24 BioPharm International eBook March 2018 www.biopharminternational.com
Outsourcing Resources Contract Biomanufacturing
Bigger is Better in Samsung's
Approach to Biomanufacturing
A different perspective on controlling fixed costs of biomanufacturing,
based on know-how from other industries, provides a competitive
edge, says the CEO of Samsung BioLogics.
RITA PETERS
T
he i n for m at ion te c h nolog y i ndu st r y i s
noted for rapid development of innovative
new products and advanced manufacturing
practices that produce affordable products.
The impact of digital technologies can be
found in all areas of consumer, transportation, man-
ufacturing, and business life.
Dig ital technolog ies and information sciences
also have helped advanced medical science and
research, a lesson that was obvious to Dr. Tae Han
K i m, CEO a nd president of Sa msu ng BioL og ics,
when he was researching new business areas for
Samsung about 10 years ago. His recommendation—
to enter the biologics drug contract manufacturing
market, an area in which it had no prior experi-
ence—leveraged the company's manufacturing and
plant construction expertise.
While solar power, electric cars, or LED lighting
may have been obvious choices for the diversified
i ndust r ia l a nd technolog y conglomerate k now n
widely for its consumer electronics and appliances,
Kim observed that the biotech industry was at a
ITSMEJUST/SHUTTERSTOCK.COM
